Filtered By:
Drug: Baclofen

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 86 results found since Jan 2013.

New Partnership Forms to Develop Breakthrough Neuromodulation Device
WeHealth, an e-health department of Servier Group, said it is in a partnership with Pathmaker Neurosystems, a pioneering clinical-stage bioelectronic medicine company. The two companies revealed plans to develop and commercialize the first neuromodulation technology designed to treat muscle spasticity non-invasively. The new technology will be known as the MyoRegulator device. The new MyoRegulator PM-200 provides a non-invasive treatment option for patients suffering from muscle spasticity, a common condition found in many patients suffering from stroke, cerebral palsy, multiple sclerosis, spinal cord injury, and traumatic...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Kristopher Sturgis Tags: Business Source Type: news

Rectal administration of baclofen at the end of life
Spasticity can be a complicating symptom of a variety of neurological conditions such as multiple sclerosis, motor neuron disease, Creutzfeldt-Jakob disease, or post-stroke. Several pharmacological treatment options are available, including baclofen, tizanidine, gabapentin, botulinum toxin A and tetrahydrocannabinol/canabidiol (1, 2). However, treatment feasibility decreases as the end of life approaches, e.g. when patients are no longer able to tolerate oral medications, the onset of action would be too long, or the initiation of parenteral drug therapy (intravenous, intrathecal) is no longer indicated or appropriate.
Source: Journal of Pain and Symptom Management - August 7, 2018 Category: Palliative Care Authors: Charlotte Selge, Claudia Bausewein, Constanze Remi Source Type: research

Effect of oral baclofen on spasticity poststroke: responders versus non-responders.
Conclusion Although the responder rate was low, some participants responded to oral baclofen. Thus, a short-term trial of oral baclofen, and quantitative and electrophysiological assessments of muscle tone and ankle clonus are recommended. PMID: 29768106 [PubMed - as supplied by publisher]
Source: Topics in Stroke Rehabilitation - May 16, 2018 Category: Neurology Authors: Mizuno S, Takeda K, Maeshima S, Shigeru S Tags: Top Stroke Rehabil Source Type: research

Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity
Medtronic (NYSE:MDT)  touted data today showing that intrathecal baclofen therapy delivered via the company’s SychroMed II infusion pump performed better than the conventional treatment for patients with severe post-stroke spasticity. The medtech titan’s SynchroMed II pump is the only device approved in the U.S. for ITB therapy. Get the full story at our sister site, Drug Delivery Business News. The post Medtronic touts therapy delivered via SynchroMed pump in patients with post-stroke spasticity appeared first on MassDevice.
Source: Mass Device - January 11, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Medtronic Source Type: news

New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity
Therapy Delivered via the Medtronic SynchroMed(TM) II Infusion System DUBLIN - January 11, 2018 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised St... Devices, Drug Delivery, Neurology Medtronic, Intrathecal Baclofen Therapy, baclofen, SynchroMed, Stroke
Source: HSMN NewsFeed - January 11, 2018 Category: Pharmaceuticals Source Type: news

Role of the continuous infusion test with an external pump for intrathecal baclofen in post-stroke spastic ambulatory patients
Discussion – conclusion Our pilot study showed that the continuous infusion test might be useful in order to evaluate the effect of different ITB doses in walking ability, helping the prediction of the appropriate candidates for ITB implantation.
Source: Annals of Physical and Rehabilitation Medicine - September 27, 2017 Category: Rehabilitation Source Type: research

Poster 462: Efficacy of Intrathecal Baclofen Therapy Compared to Conventional Oral Treatment in Post-Stroke Spasticity: An International Multicenter Randomized Controlled Trial (SISTERS)
Michael Creamer: I Have No Relevant Financial Relationships To Disclose
Source: PM and R - September 1, 2017 Category: Rehabilitation Authors: Michael J. Creamer, Geoffrey C. Cloud, Peter PK. Kossmehl, Michael R. Yochelson, Gerard E. Francisco, Anthony B. Ward, Joerg H. Wissel, Mauro Zampolini, Meghann M. Loven, Nathalie Berthuy, Abdallah Abouihia, Alessandra Calabrese, Leopold LS. Saltuari Tags: Category: Neurological Rehabilitation Source Type: research

Intrathecal Baclofen Bolus Reduces Exaggerated Extensor Coactivation during Pre-Swing and Early-Swing of Gait after Acquired Brain Injury
Pathological muscle activation patterns during gait are common after acquired brain injury (ABI). In an early study of 26 stroke patients, Knutsson and Richards (1979) monitored the hip abductor, hip adductors, quadriceps, hamstrings, triceps surae, and tibialis anterior (TA) muscles and qualitatively described 3 different patterns of abnormal muscle activation during gait, one of which is characterized by coactivation of several muscle groups during the end of swing and throughout the main part of the stance phase.
Source: Clinical Neurophysiology - February 28, 2017 Category: Neuroscience Authors: John W. Chow, Stuart A. Yablon, Dobrivoje S. Stokic Source Type: research

Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.
In this study we compared the efficacy and safety of baclofen vs tolperisone in spasticity. One hundred fifty patients with cerebral palsy or post stroke or spinal cord injury associated spasticity were enrolled in present study. Group I comprised of Seventy-five patients receiving baclofen and group II comprised of 75 patients receiving tolperisone. For efficacy measurement 4 evaluation methods were used, 1) Modified Ashworth Scale for muscle tone, 2) Medical research council scale for muscle strength and 3) Barthel Index for functional outcome 4) Coefficient of efficacy. In efficacy evaluation, both groups showed signifi...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 9, 2017 Category: Drugs & Pharmacology Authors: Agarwal S, Patel T, Shah N, Patel BM Tags: Biomed Pharmacother Source Type: research

Long-term Dosing of Intrathecal Baclofen in the Treatment of Spasticity after Acquired Brain Injury
Conclusion Despite the long-term use of ITB therapy in this cohort, the mean daily dose of intrathecal baclofen continued to require adjustments. There was no significant difference in the mean daily dose between patients with a diagnosis of TBI, stroke, or HIE. A complex dosing pattern was used more frequently in patients with stroke.
Source: PMandR - January 7, 2017 Category: Rehabilitation Source Type: research

Quantitative pharmacokinetic –pharmacodynamic modelling of baclofen‐mediated cardiovascular effects using BP and heart rate in rats
Conclusions and ImplicationsThe systems pharmacology model developed fits baclofen‐mediated changes in MAP and HR well. The findings correlate with known mechanisms of baclofen pharmacology and suggest that similar models using limited parameter sets may be useful to predict the cardiovascular effects of other pharmacologically active substances.
Source: British Journal of Pharmacology - August 24, 2016 Category: Drugs & Pharmacology Authors: Harriet Kamendi, Herbert Barthlow, David Lengel, Marie ‐Eve Beaudoin, Debra Snow, Jerome T Mettetal, Russell A Bialecki Tags: RESEARCH PAPER Source Type: research

Baclofen Toxicity Causing Acute, Reversible Dyskinesia.
Abstract The following unique case demonstrates an episode of acute dyskinesia secondary to oral baclofen toxicity. We discuss an 80-year-old man with a history of Stage III chronic kidney disease, coronary artery disease, diabetes and stroke who presented to the Emergency Department with new onset of behavioral changes and irregular jerking movements. The patient had been recently prescribed baclofen 10mg twice daily for a back strain he suffered; he subsequently was admitted to the hospital, and his symptoms resolved within 48 hours of admission and discontinuance of baclofen. PMID: 27234296 [PubMed - as supplied by publisher]
Source: Journal of Medical Toxicology - May 26, 2016 Category: Toxicology Authors: Niehaus MT, Elliott NC, Katz KD Tags: J Med Toxicol Source Type: research

Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life
Conclusions Long-term treatment with intrathecal compared with oral baclofen is associated with reduced spasm frequency and severity as well as greater dose stability. These benefits must be weighed against the risks of internal pump and catheter placement in patients considering intrathecal baclofen therapy.
Source: PMandR - November 22, 2015 Category: Rehabilitation Source Type: research

Intrathecal versus Oral Baclofen; a Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue and Quality of Life
Conclusions Long-term treatment with intrathecal compared to oral baclofen is associated with reduced spasm frequency and severity as well as greater dose stability. These benefits must be weighted against the risks of internal pump and catheter placement in patients considering intrathecal baclofen therapy.
Source: PMandR - October 21, 2015 Category: Rehabilitation Source Type: research

Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review
ConclusionSignificant differences in dosing were found between diagnoses and trended to differ by ambulatory status at the end of the study, and similar trends could be observed in achieving initial stable dose.
Source: Neuromodulation: Technology at the Neural Interface - October 1, 2015 Category: Biotechnology Authors: Jacob S. Clearfield, Mary Elizabeth S. Nelson, John McGuire, Lisa E. Rein, Sergey Tarima Tags: Clinical Research Source Type: research